Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

gladpick 49 posts  |  Last Activity: 15 hours ago Member since: Jan 24, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Barclays Healthcare Conference

    by papaalien2000 Mar 16, 2016 3:45 AM
    gladpick gladpick Mar 17, 2016 8:44 AM Flag

    Totally agree with you. It looks like they do not give a damn about PPS. Evaluating the interview, I thought it was a disaster. Only the negative was accentuated. I personally believe VRTX should not participate in these types of conferences unless it has something good to announce. The format of these types of conferences are such that the interviewer is almost in total control by only asking questions that suits his/her firm's agenda--in this case just about all the questions asked were the types that led to the warts that hang around the CF drugs. For example the interviewer did not ask a single question about the status of any non CF drugs in the pipeline and Stuart was not smart enough to steer the discussion into other products--not that there are many but, nevertheless it could have had a better affect.

  • Reply to

    How much is thing worth in a buyout?

    by garroty Mar 9, 2016 1:22 PM
    gladpick gladpick Mar 16, 2016 3:35 PM Flag

    You mean Hillary the baitch?

  • Reply to

    Barclays Healthcare Conference

    by papaalien2000 Mar 16, 2016 3:45 AM
    gladpick gladpick Mar 16, 2016 2:35 PM Flag

    In my opinion the only hope we have is for Orkambi sales to increase. I think some investors have been spooked by all the talk of Orkambi discontinuations which management does not seem to have a good handle on. The hope is that some of those who discontinued due to adverse side effects may try to go back on Orkambi. You may want to listen to the yesterday's taped conference call that Barcley conducted with Stuart.

    Good luck to all of us longs.

  • Reply to

    Barclays Healthcare Conference

    by papaalien2000 Mar 16, 2016 3:45 AM
    gladpick gladpick Mar 16, 2016 11:35 AM Flag

    It allows Leiden to PRETEND he is working hard to boost pps. So far his actions at the helm have not had very good results for pps because investors for the most part consider VRTX as a one drug pony with several competing drugs in the works.

    In my opinion the BOD should fire Leiden and find someone who is capable of beefing the pipeline.

    VRTX has a bloated number of employees which must include many scientists. My question is what are all of these scientists doing? How about having some of these scientists work on other possible drugs and if they pass phase I then find big pharma to partner with VRTX whereby they can underwrite the cost of phase 2 and 3 and if successful VRTX could get royalties on the sales. I think I have the answer to that as to why it will not happen. It is because VRTX leadership has BIG egos and consider turning their inventions to others for development beneath them!

  • Reply to

    How much is thing worth in a buyout?

    by garroty Mar 9, 2016 1:22 PM
    gladpick gladpick Mar 10, 2016 12:35 PM Flag

    As has been mentioned before, in addition to Leiden getting all of those free shares, and other companies developing Cf drugs to compete with VRTX and the lack of other products being pushed through the pipeline, the other factor that is affecting pps is the Hillary factor. Threats of drug pricing, even though I doubt it it will happen with the republicans in control of both houses, nevertheless, has spooked investors.

    Here is the statistics about biotechs for the past 6 months:

    VRTX down 38%
    NBI down 28%
    BTK down 28%
    IBB down 28%

    I believe VRTX has gotten hit harder because of the above mentioned reasons unique to it.

  • Reply to

    How much is thing worth in a buyout?

    by garroty Mar 9, 2016 1:22 PM
    gladpick gladpick Mar 9, 2016 4:17 PM Flag

    I hope I am wrong about this but I just do not believe VRTX is a good takeover candidate. Its present market cap is $20+B. A 1/3 premium makes a buyout cost around $27B which makes it somewhat a large investment for even some of the pharma biggies. Add to that Leiden's concentration on CF at the expense of slowing other products through research as well as competition from other drug companies with their CF drugs nipping at VRTX's heels-- I simply am not very optimistic about a buyout. My hope is that VRTX's additional CF drugs will cover more patients and revenue would increase soon.

    As I said I hope I am wrong because unfortunately a good portion of my investment is tied in this stock.

  • Reply to

    Need your input

    by gladpick Mar 2, 2016 3:52 PM
    gladpick gladpick Mar 3, 2016 9:25 AM Flag

    "Forget HR for a second. "

    Under HR, in addition to several failed costly drug trials due to his faulty designs, here is what has happened to the stock during his time at NKTR:

    NKTR DOWN 48.16%
    IBB UP 253.15%
    NBI UP 253+%
    BTK UP 338.28%

    And you are saying forget about HR. Give me a break. He has been at it for 9 years and has been milking the company with his undeserved high salary and options -- isn't 9 years enough of this?

  • gladpick by gladpick Mar 2, 2016 3:52 PM Flag

    Is there anyone on this board who has regularly posted messages (HR and his cronies excluded) that believes HR should keep his job? If so please explain why. I will try to have an open mind and am willing to be educated.

  • Reply to

    NKTR true value.

    by kklausbeckerman Mar 2, 2016 12:57 PM
    gladpick gladpick Mar 2, 2016 3:47 PM Flag

    "Would like to see the Board have some backbone on that front"

    Are you kidding. The board members are in bed with that HR SOB.

VRTX
84.42-0.28(-0.33%)May 23 4:00 PMEDT